display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced mGC or mGEJC
mGC or mGEJC - M - HER2 negative
anti-PD-(L)1
avelumab based treatment
avelumab alone JAVELIN Gastric 100

Study type: